BACKGROUND: Selected patients with unresectable colorectal liver metastases (CLM) may be rendered resectable after systemic chemotherapy. We reviewed the evidence of downsizing systemic chemotherapy followed by rescue liver surgery in patients with initially unresectable CLM. METHODS: Literature search of databases (Medline and PubMed) to identify published studies of neoadjuvant chemotherapy followed by liver resection in patients with initially unresectable CLM was undertaken and focused on response rate of chemotherapy and survival outcomes. RESULTS: Ten observational studies were reviewed. A total of 1,886 patients with initially unresectable CLM underwent systemic chemotherapy. An objective response was observed in 64% (range, 43-79%) of patients after systemic chemotherapy. Of these, 22.5% underwent macroscopically curative liver resection. Median overall survival was 45 (range, 36-60) months with 19% of patients alive and recurrence-free. CONCLUSIONS: Current evidence suggests that downsizing systematic chemotherapy followed by rescue liver resection is safe and effective for selected patients with initially unresectable CLM. Further studies are required to examine response rates and secondary resectability using new targeted molecular therapy-based regimens.
BACKGROUND: Selected patients with unresectable colorectal liver metastases (CLM) may be rendered resectable after systemic chemotherapy. We reviewed the evidence of downsizing systemic chemotherapy followed by rescue liver surgery in patients with initially unresectable CLM. METHODS: Literature search of databases (Medline and PubMed) to identify published studies of neoadjuvant chemotherapy followed by liver resection in patients with initially unresectable CLM was undertaken and focused on response rate of chemotherapy and survival outcomes. RESULTS: Ten observational studies were reviewed. A total of 1,886 patients with initially unresectable CLM underwent systemic chemotherapy. An objective response was observed in 64% (range, 43-79%) of patients after systemic chemotherapy. Of these, 22.5% underwent macroscopically curative liver resection. Median overall survival was 45 (range, 36-60) months with 19% of patients alive and recurrence-free. CONCLUSIONS: Current evidence suggests that downsizing systematic chemotherapy followed by rescue liver resection is safe and effective for selected patients with initially unresectable CLM. Further studies are required to examine response rates and secondary resectability using new targeted molecular therapy-based regimens.
Authors: Marco Ravanelli; Giorgio Maria Agazzi; Elena Tononcelli; Elisa Roca; Paolo Cabassa; Gianluca Baiocchi; Alfredo Berruti; Roberto Maroldi; Davide Farina Journal: Radiol Med Date: 2019-06-06 Impact factor: 3.469
Authors: Jean-Michel Aubin; Alexsander K Bressan; Sean C Grondin; Elijah Dixon; Anthony R MacLean; Sean Gregg; Patricia Tang; Gilaad G Kaplan; Guillaume Martel; Chad G Ball Journal: Can J Surg Date: 2018-08 Impact factor: 2.089
Authors: R Vera; M Gomez Dorronsoro; S Lopez-Ben; A Viudez; B Queralt; I Hernandez; M R Ortiz-Duran; C Zazpe; J Soriano; I Amat; J Herrera Cabezón; E Diaz; A Codina-Barreras; X Hernandez-Yagüe; A Quera; J Figueras Journal: Clin Transl Oncol Date: 2013-12-12 Impact factor: 3.405
Authors: Francesco Ardito; Maria Vellone; Alessandra Cassano; Agostino M De Rose; Carmelo Pozzo; Alessandro Coppola; Bruno Federico; Ivo Giovannini; Carlo Barone; Gennaro Nuzzo; Felice Giuliante Journal: J Gastrointest Surg Date: 2012-12-08 Impact factor: 3.452
Authors: Osama H Hamed; Neil H Bhayani; Gail Ortenzi; Jussuf T Kaifi; Eric T Kimchi; Kevin F Staveley-O'Carroll; Niraj J Gusani Journal: HPB (Oxford) Date: 2012-12-27 Impact factor: 3.647
Authors: T F Ulmer; C de Jong; A Andert; P Bruners; C M Heidenhain; W Schoening; M Schmeding; U P Neumann Journal: World J Surg Date: 2017-01 Impact factor: 3.352